Carfilzomib

{
  "id": "MLC-T-ONC-001457",
  "term": "Carfilzomib",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used alone or with other drugs to treat adults with multiple myeloma that came back or did not get better after treatment with one or more other therapies. It is also being studied in the treatment of other types of cancer. Carfilzomib blocks the action of enzymes called proteasomes, which may help keep cancer cells from growing and may kill them. It is a type of proteasome inhibitor. Also called Kyprolis.",
    "An epoxomicin derivate with potential antineoplastic activity. Carfilzomib irreversibly binds to and inhibits the chymotrypsin-like activity of the 20S catalytic core subunit of the proteasome, a protease complex responsible for degrading a large variety of cellular proteins. Inhibition of proteasome-mediated proteolysis results in an accumulation of polyubiquinated proteins, which may lead to cell cycle arrest, induction of apoptosis, and inhibition of tumor growth."
  ],
  "abbreviation": "CFZ",
  "synonyms": [
    "Kyprolis"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/carfilzomib/"
}